Macquarie Group LTD Atara Biotherapeutics, Inc. Transaction History

Macquarie Group LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.85 - $8.73 $1,821 - $5,578	-639 Closed	0 $2,000
Q4 2021 Feb 11, 2022	SELL	$14.7 - $19.89 $39,278 - $53,146	-2,672 Reduced 80.7%	639 $10,000
Q3 2021 Nov 12, 2021	BUY	$11.99 - $17.9 $30,382 - $45,358	2,534 Added 326.13%	3,311 $59,000
Q1 2021 May 14, 2021	SELL	$14.0 - $20.72 $5,166 - $7,645	-369 Reduced 32.2%	777 $11,000
Q2 2020 Aug 11, 2020	BUY	$7.53 - $14.93 $8,629 - $17,109	1,146 New	1,146 $17,000
Q3 2018 Nov 15, 2018	SELL	$35.05 - $43.5 $66,595 - $82,650	-1,900 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$35.15 - $51.45 $66,785 - $97,755	1,900 New	1,900 $70,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.21B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.